BackLAVA Therapeutics NV Overview

LAVA Therapeutics NV Other Current Liabilities

Latest other current liabilities for LVTX: $-32M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$-32.47M
618.73% YoYΔ $-38.73M vs prior year quarter

Peer trimmed avg / median

Loading

LAVA Therapeutics NV Other Current Liabilities History

Loading

LAVA Therapeutics NV vs. peers: Other Current Liabilities Comparison

Loading

LAVA Therapeutics NV Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

LAVA Therapeutics NV (LVTX) FAQ

LAVA Therapeutics NV's other current liabilities stands at $-32M as of September 2025. That compares with $6.3M in the prior-year period — down 618.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

LAVA Therapeutics NV reported $-32M in other current liabilities versus $6.3M a year earlier — a 618.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $6.3M in the prior-year period — down 618.7% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how LAVA Therapeutics NV's other current liabilities evolved across reporting periods, while the comparison chart places LVTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. LAVA Therapeutics NV's reading of $-32M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.